Plakous Therapeutics is focused on developing innovative regenerative biotherapeutics aimed at addressing inflammation-driven diseases across various age groups. Central to their approach is the use of human placental extract (HPE), a biologic that possesses anti-inflammatory and immunomodulatory properties. This extract is derived from full-term placental tissue and is processed to retain over 950 different proteins and chemokines that play crucial roles in cellular responses. By inhibiting inflammation and preventing the over-activation of immune cells, HPE aims to restore and repair organs affected by diseases such as necrotizing enterocolitis (NEC) and osteoarthritis, demonstrating significant preclinical efficacy in reducing disease severity and protecting joint cartilage.

The company is also targeting a range of clinical conditions, including neurodevelopmental injuries in premature infants, bronchopulmonary dysplasia, acute respiratory distress syndrome, and neurodegenerative diseases like Alzheimer's and Parkinson's. Their research indicates that HPE may promote oligodendrocyte proliferation, which could address the inflammatory causes of neurodegeneration. Plakous Therapeutics is committed to advancing the understanding and application of HPE in treating these complex medical challenges, with the goal of becoming a leader in the commercialization of safe and effective birth tissue biotherapeutics.

United States

We are dedicated to creating innovative solutions for the most complex medical challenges, utilizing our unique approach to regenerative medicine. Protego-PD™ is a biologic with anti-inflammatory and immunomodulatory capabilities that work together to orchestrate a complex cellular response to restore and repair organs damaged by inflammation-driven diseases.

Plakous Therapeutics

Company Details